Market capitalization | $175.06m |
Enterprise Value | $136.69m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 6.93 |
P/S ratio (TTM) P/S ratio | 8.88 |
P/B ratio (TTM) P/B ratio | 5.11 |
Revenue growth (TTM) Revenue growth | -21.01% |
Revenue (TTM) Revenue | $19.72m |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
4 Analysts have issued a MediWound Ltd. forecast:
4 Analysts have issued a MediWound Ltd. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 20 20 |
21%
21%
|
|
Gross Profit | 2.45 2.45 |
78%
78%
|
|
EBITDA | -16 -16 |
100%
100%
|
EBIT (Operating Income) EBIT | -17 -17 |
88%
88%
|
Net Profit | -28 -28 |
126%
126%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.
Head office | Israel |
CEO | Ofer Gonen |
Employees | 100 |
Founded | 2000 |
Website | www.mediwound.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.